% 0期刊文章%拉斐尔施耐德% Koroboshka Brand-Arzamendi %盖Lim %丽莎Eunyoung李%梅兰妮Guenette % Suradech Suthiphosuwan % Jiwon哦一个Aditya Bharatha % % T等离子胶质原纤维酸性蛋白水平与不利的影像放射检查隔离措施综合症(p1 - 3.003) % D R 10.1212 / WNL 2023%。0000000000202516 % J首页神经病学% P V 100% N 17补充2% 2386% X目的:研究等离子体是否GFAP (pGFAP)水平与成像技术措施,可以用作预后患者血液生物标志物RIS (pwRIS)。背景:放射检查孤立综合征(RIS)描述了人没有以前或现在MS症状特征病变在脑MRI与女士(pwm)。没有明确如何管理pwRIS以证据为基础的指导方针。成像和blood-based生物标志物进行承诺pwRIS潜在工具指导治疗决策。我们曾表明,大多数pwRIS显示高比例的白质病变(wml)展示中央静脉(CVS)和至少一个顺rim病变,慢性的成像生物标志物,活跃的wml女士(PRL)。胶质原纤维酸性蛋白(GFAP)是一个潜在的血液生物标志物的评价但是,女士pwRIS GFAP尚未研究,特别是与CVS和以“。设计/方法:32 pwRIS接受3 t大脑和颈部脊髓磁共振成像和测量水平pGFAP HD-1 Simoa平台(Quanterix)。斯皮尔曼相关系数是用来评估的相关性。结果:pGFAP水平将积极与黑洞的数量,CVS + wml,是否使用的斯皮尔曼相关系数(p < 0.05)。结论:本试验研究是第一个证明pGFAP水平正相关的数量:黑洞,CVS + wml,是否在pwRIS。考虑到黑洞之间的关系,建立以“和疾病进展,女士pwRIS pGFAP高水平可能增加患临床女士和残疾的风险。前瞻性验证正在确认pwRIS GFAP的预后价值。Disclosure: Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Mrs. Brand-Arzamendi has nothing to disclose. Timothy R. Lim has nothing to disclose. Lisa Eunyoung Lee has nothing to disclose. Melanie Guenette has nothing to disclose. Dr. Suthiphosuwan has nothing to disclose. Aditya Bharatha has nothing to disclose. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from EMD-Serono. The institution of Dr. Oh has received research support from Biogen-Idec. %U